Protocol Ledger

NCT05218655 · Phase III · COMPLETED

A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease

Interventional Phase III clinical trial protocol NCT05218655 sponsored by PTC Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-22 Enrollment: 101 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05218655
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)101 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05218655
Protocol FieldVerified Registry Value
NCT IdentifierNCT05218655
Consolidated Lead SponsorPTC Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment101 participants (ACTUAL)
Registered Start Date2022-06-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI